Boston Scientific (BSX) Net Income towards Common Stockholders (2009 - 2026)

Boston Scientific (BSX) has 18 years of Net Income towards Common Stockholders data on file, last reported at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 98.96% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $3.6 billion (up 75.44% YoY), and the FY2025 full-year result was $2.9 billion, up 56.4% from the prior year.
• Net Income towards Common Stockholders grew to $1.3 billion in Q1 2026, from $672.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $1.3 billion in Q1 2026 to a low of $97.0 million in Q1 2022.
• A 5-year average of $488.6 million and a median of $495.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders tumbled 70.34% in 2022 and surged 300.79% in 2023, its largest moves.
• Tracing BSX's Net Income towards Common Stockholders over 5 years: stood at $126.0 million in 2022, then surged by 300.79% to $505.0 million in 2023, then grew by 11.88% to $565.0 million in 2024, then rose by 18.94% to $672.0 million in 2025, then jumped by 99.55% to $1.3 billion in 2026.
• Business Quant data shows BSX's Net Income towards Common Stockholders at $1.3 billion in Q1 2026, $672.0 million in Q4 2025, and $755.0 million in Q3 2025.